Biomarker Research Group, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Hungary.
Proteomics Core Facility, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Hungary.
FEBS Open Bio. 2019 May;9(5):1020-1028. doi: 10.1002/2211-5463.12637. Epub 2019 Apr 23.
Glaucoma is a multifactorial neurodegenerative disease that causes impaired vision and, in advanced cases, blindness. The increasing prevalence of glaucoma due to an ageing population has necessitated the identification of suitable biomarkers for the early detection of the disease. Aqueous humour (AH) has been proposed as a source of biomarkers, but it can only be collected using a minor, yet invasive surgical intervention. Tears, however, are constantly available and can be collected any time via noninvasive methods. In order to examine the utility of tear as a surrogate for aqueous humour in biomarker development, we compared the levels of 27 cytokines and chemokines in paired samples of tear and aqueous humour using a Luminex multiplex immunobead-based technique. Significantly higher levels of cytokines in tear compared to aqueous humour were detected suggesting that tear and aqueous humour are not identical in terms of inflammation response. Furthermore, the levels of IFN-γ, GM-CSF and IL-5 in tear were significantly lower in patients who developed complications after one year, but no statistically significant changes in cytokine levels were observed in aqueous humour. These three molecules may have potential as predictive biomarkers for the appearance of late flap-related complications of trabeculectomy.
青光眼是一种多因素的神经退行性疾病，可导致视力受损，在晚期病例中可导致失明。由于人口老龄化，青光眼的患病率不断上升，因此需要确定合适的生物标志物来早期发现这种疾病。房水（AH）已被提议作为生物标志物的来源，但只能通过小的、但具有侵入性的手术干预来采集。然而，眼泪是不断产生的，可以通过非侵入性方法随时采集。为了研究眼泪作为房水生物标志物开发替代物的效用，我们使用基于 Luminex 多重免疫珠的技术比较了配对的眼泪和房水样本中 27 种细胞因子和趋化因子的水平。与房水相比，眼泪中细胞因子的水平明显更高，这表明眼泪和房水在炎症反应方面并不相同。此外，在一年后出现并发症的患者中，眼泪中的 IFN-γ、GM-CSF 和 IL-5 水平明显降低，但房水中的细胞因子水平没有观察到统计学上的显著变化。这三个分子可能具有作为小梁切除术晚期瓣相关并发症出现的预测生物标志物的潜力。
